• Werewolf Therapeutics director Luke Evnin sold 143,199 common shares on July 6-7.
• Sales priced at weighted averages of $0.32 on July 6, $0.31 on July 7.
• Beneficial ownership reported indirectly fell to zero shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001134657-26-000020), on July 08, 2026, and is solely responsible for the information contained therein.